Treatment of postmenopausal osteoporosis -a) Tamoxifenb) Progesterone c) Estrogend) Alendronatee) Calcitonin
**Core Concept**
Postmenopausal osteoporosis is a condition characterized by decreased bone density and increased risk of fractures, resulting from the decline in estrogen levels after menopause. Effective treatment involves medications that either increase bone formation or decrease bone resorption.
**Why the Correct Answer is Right**
Alendronate is a bisphosphonate, a class of medications that inhibit osteoclast-mediated bone resorption. By reducing bone breakdown, alendronate increases bone density and reduces the risk of fractures in postmenopausal women with osteoporosis. Its mechanism of action involves the inhibition of farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway, leading to a decrease in the formation of isoprenoids required for protein prenylation and ultimately, osteoclast function.
**Why Each Wrong Option is Incorrect**
**Option A:** Tamoxifen is a selective estrogen receptor modulator (SERM) primarily used in the treatment and prevention of breast cancer. While it has some estrogenic effects on bone, it is not a first-line treatment for postmenopausal osteoporosis.
**Option B:** Progesterone has a varying effect on bone density, depending on the population studied. However, it is not a standard treatment for postmenopausal osteoporosis.
**Option C:** Estrogen replacement therapy can help prevent bone loss in postmenopausal women, but it is not always recommended due to potential risks and side effects.
**Option E:** Calcitonin is a hormone that decreases osteoclast activity and is used to treat osteoporosis, but it is not as effective as bisphosphonates like alendronate and has a shorter duration of action.
**Clinical Pearl / High-Yield Fact**
Bisphosphonates like alendronate are often recommended as first-line treatment for postmenopausal osteoporosis due to their efficacy in increasing bone density and reducing fracture risk.
**Correct Answer: D. Alendronate**